ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Myosteatosis Predicts Poor Prognosis in Patients With Castration-Resistant Prostate Cancer Treated With Enzalutamide.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesProstate cancer prognostication has traditionally emphasized tumor-related factors (e.g., Gleason score and metastatic burden). Emerging evidence suggests that physical (host) factors influence outcomes. This study evaluated whether physical factors, including myosteatosis and sarcopenia, are prognostic factors in patients with androgen receptor signaling inhibitor-naïve, castration-resistant prostate cancer.
methodsWe retrospectively analyzed 117 androgen receptor signaling inhibitor-naïve patients with castration-resistant prostate cancer who received enzalutamide treatment at The University of Osaka Hospital between 2014 and 2024. Myosteatosis and sarcopenia were derived from pretreatment abdominal computed tomography. The primary endpoint was failure-free survival. Multivariate Cox proportional hazards analysis was performed to identify independent prognostic factors.
resultsMyosteatosis and sarcopenia were present in 49 (42%) and 46 (39%) patients, respectively. In univariate analyses, the Charlson comorbidity index, body mass index, and sarcopenia demonstrated no significant association with failure-free survival, whereas myosteatosis and distant metastasis were associated with a shorter failure-free survival. In multivariable analysis, myosteatosis remained an independent predictor of shorter failure-free survival (hazard ratio 1.91, 95% confidence interval 1.22-2.99, p < 0.01). The median failure-free survival was 6 and 17 months with and without myosteatosis, respectively (p < 0.01).
conclusionsMyosteatosis is an independent failure-free survival predictor in patients with androgen receptor signaling inhibitor-naïve castration-resistant prostate cancer treated with enzalutamide. Computed tomography-based evaluation of muscle quality may be useful for predicting the outcome of androgen receptor signaling inhibitors in patients with castration-resistant prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.